Picture of Nanobac Pharmaceuticals logo

NNBP Nanobac Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-1.85%
3m-3.16%
6m-11.63%
1yr-15.6%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-1362.95%
Return on Equityn/a
Operating Margin-35966.67%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 200831st Dec 2009
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2008 / 2009

Blurred out image of Nanobac Pharmaceuticals EPS forecast chart

Profile Summary

Nanobac Pharmaceuticals, Incorporated (Nanobac) is a research-based, bio-lifescience company. The Company is primarily engaged in the discovery and development of products and services to improve people’s health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as nanobacteria. Its research is directed toward establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease. Nanobac’s drug discovery and development is focused on new and existing compounds that inhibit, destroy or neutralize CNPs. Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products (blood and tissue tests) include assays, antibodies and reagents for recognizing CNPs.

Directors

Last Annual
December 31st, 2007
Last Interim
December 31st, 2007
Incorporated
June 15th, 1994
Public Since
June 21st, 2001
No. of Shareholders
250
No. of Employees
1
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
249,506,760
Blurred out image of a map
Address
5025 W Lemon St, TAMPA, 33609-1101
Web
Phone
+1 8133774434
Auditors
Rotenberg Meril Solomon Bertiger & Guttilla, P.C.

NNBP Share Price Performance

Similar to NNBP

Picture of Acorda Therapeutics logo

Acorda Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Actavia Life Sciences logo

Actavia Life Sciences

us flag iconPink Sheets on Nasdaq

Picture of Acura Pharmaceuticals logo

Acura Pharmaceuticals

us flag iconPink Sheets on Nasdaq

Picture of Adhera Therapeutics logo

Adhera Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Ramoil Management logo

Ramoil Management

us flag iconPink Sheets on Nasdaq

FAQ